Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, Stübig T, Wolschke C, Ayuk F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander AR.
Kröger N, et al.
Bone Marrow Transplant. 2013 Mar;48(3):403-7. doi: 10.1038/bmt.2012.142. Epub 2012 Aug 6.
Bone Marrow Transplant. 2013.
PMID: 22863722
Clinical Trial.